Navigation Links
Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
Date:1/28/2013

CHARLESTON, S.C., Jan. 28, 2013 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting related to opioid analgesics and other pain associated disease states, announced today that patient enrollment has begun for the company's pivotal Phase 3 clinical trial for its first product, CL-108, for the treatment of moderate to severe pain.

"The initiation of this study marks the culmination of work by many people," said Dr. Bernard P. Schachtel , Chief Scientific Officer of Charleston.  "In addition to input by our scientific, clinical and regulatory advisors, the investigators at the research centers where this study is being conducted also contributed to the protocol."  Dr. Schachtel noted in particular the advice of Dr. Elliot V. Hersh , Professor of Oral & Maxillofacial Surgery and Pharmacology at the University of Pennsylvania, where Dr. Hersh is Principal Investigator for the trial.  "As exemplified by the enthusiasm and dedication of the many doctors, nurses, study coordinators, and other researchers at our recent Investigators Meeting," Dr. Schachtel continued, "this study offers the rare and exciting opportunity to research a truly novel indication, the treatment of both moderate to severe pain and the nausea and vomiting commonly associated with its treatment."  

"This day represents a major milestone for Charleston in our quest to develop differentiated and innovative pain products," said Paul Bosse , President and Chief Executive Officer of Charleston.  "I am proud of the Charleston team, specifically the critical roles they played in drug manufacturing, regulatory affairs and project ma
'/>"/>

SOURCE Charleston Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
2. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
3. IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
4. Pisgah Laboratories, Inc. Scores a Triple Play in the World Series Against Prescription Drug Abuse
5. Abuse-Deterrent Medication Developer, Pisgah Laboratories, Achieves Top 5 Technologies Ranking
6. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
7. SuccessEHS "Forward Together" Customer Conference Begins
8. Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial
9. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
10. Siteman Cancer Center at Barnes-Jewish and Washington University Begins Imaging with First ViewRay System
11. Countdown Begins For AdvaMed 2012: The Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 2, 2011 ViroPharma Incorporated (Nasdaq: VPHM ) ... officer of ViroPharma, will present at the Jefferies 2011 Global ... 2011.  The conference is being held in New York City. ... through www.viropharma.com and available for a period of ...
... be presented in a poster at the 2011 Annual Meeting ... in Chicago, Illinois June 3-7 by researchers from The University ... that a laboratory test developed by Biocept, Inc. for the ... Disseminated Tumor Cells (DTCs) can provide potentially valuable information to ...
Cached Medicine Technology:MD Anderson and Biocept Scientists to Present Poster at ASCO on Disseminated Tumor Cells (DTCs) in Bone Marrow and Circulating Tumor Cells (CTCs) in Blood in Early Stage Breast Cancer Patients 2MD Anderson and Biocept Scientists to Present Poster at ASCO on Disseminated Tumor Cells (DTCs) in Bone Marrow and Circulating Tumor Cells (CTCs) in Blood in Early Stage Breast Cancer Patients 3
(Date:4/20/2014)... A single type of cell in the lining ... invasive bladder cancer, according to researchers at the Stanford ... mice, is the first to pinpoint the normal cell ... It,s also the first to show that most bladder ... one cell, and explains why many human bladder cancers ...
(Date:4/18/2014)... published online in The Gerontologist ... is associated with a decrease in anxiety about death ... control over their lives. In particular, listening to gospel ... death and an increase in sense of control. , ... and men, and individuals of both low- and high-socioeconomic ...
(Date:4/18/2014)... one of your worst memories? How did it make ... during a negative personal experience, such as how sad ... to emotional distress, especially when you can,t stop thinking ... up, thinking about the context of the memories, rather ... effective way to alleviate the negative effects of these ...
(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/17/2014)... The presence of chronic inflammation in benign prostate ... cancer, and this association was found even in ... to a study published in Cancer Epidemiology, ... American Association for Cancer Research. , An analysis ... of the placebo arm of the Prostate Cancer ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Religious music brings benefit to seniors' mental health 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... efficacy of a malaria drug are being questioned by ... be withdrawn. Manufacturer GlaxoSmithKline markets the anti-malarial drug Malarone ... at preventing the aggressive falciparum strain of malaria, but ... the Consumers’ Association – says the evidence for this ...
... Depression is not the only factor contributing to a heightened ... suggest that suicide is a real risk when people suffer ... link - people with panic disorder often suffer from depression. ... ,However, a new study by doctors at Cleavland State ...
... often handled in a casual “insouciant” manner, with up ... receiving appropriate drugs, researchers say. Around 30,000 people are ... one-third can be expected to continue on long-term medication. ... College London have found that some epilepsy treatment regimes ...
... raise the risk of heart disease through causing inflammation of the ... scene for heart disease. A new study uncovers a link between ... Researchers at the University of Buffalo find that people with gum ... may be that oral bacteria enter the circulation via the gums, ...
... normal blood pressure is essential in the prevention of ... researchers. Dr Jan Staessen and colleagues from Leuven, in ... pharmacological properties of antihypertensive drugs or the reduction of ... hypertensive patients., // ,As part of a ...
... is little benefit in replacing older and cheaper antibiotics ... acute, uncomplicated sinusitis, according to US researchers. Researchers at ... determine whether the symptoms could be treated with older ... expensive (second-line) antibiotics. // ,Dr Jay Piccirillo ...
Cached Medicine News:
A quarter-vision dispensing case or table with a 6" high glass display area and halogen lights. Based on size of case, enjoy either 4, 5.5, 7 or 8 square feet respectively of elegant shelf space for ...
A compact showcase unit. Made with tempered glass, one, two or three adjustable shelves, a door with a safety lock. Equipped with fluorescent lighting and levelers. Display is available in various si...
Hoya Vision Care is focused on providing the best available most technically advanced and highest quality eye care products and services to the dispensing optometrist, ophthalmologist and optician....
... Essilor Laboratories of America ... trusted, spectacle lens lab network ... America. With in-house Crizal coating ... service and ensure premium quality ...
Medicine Products: